Jaw Osteonecrosis in Patients Treated with Bisphosphonates: An Ultrastructural Study

被引:11
作者
Perrotta, I. [1 ]
Cristofaro, M. G. [2 ]
Amantea, M. [2 ]
Russo, E. [3 ]
De Fazio, S. [3 ]
Zuccala, V. [4 ,5 ]
Conforti, F. [4 ,5 ]
Amorosi, A. [4 ,5 ]
Donato, G. [4 ,5 ]
Tripepi, S. [1 ]
Giudice, M.
机构
[1] Univ Calabria, Dept Ecol, I-87036 Cosenza, Italy
[2] Magna Graecia Univ Catanzaro, Dept Oral & Maxillofacial Surg, Catanzaro, Italy
[3] Univ Catanzaro, Sch Med, Dept Expt & Clin Med, Catanzaro, Italy
[4] Fdn Ric & Cura Tumori Tommaso Campanella, Catanzaro, Italy
[5] Magna Graecia Univ Catanzaro, Sch Med, Dept Pathol, Catanzaro, Italy
关键词
bisphosphonates; jaw osteonecrosis; bone metastases; OSTEOCLASTS IN-VITRO; ZOLEDRONIC ACID; INDUCE APOPTOSIS; BONE METASTASES; BREAST-CANCER; AVASCULAR NECROSIS; MEVALONATE PATHWAY; CELLS; MECHANISMS; RESORPTION;
D O I
10.3109/01913121003729806
中图分类号
TH742 [显微镜];
学科分类号
摘要
Osteonecrosis of the jaw is a severe bone disorder traditionally associated with periodontal disease, local malignancy, chemotherapy, glucocorticoid therapy, or trauma. Recently a growing number of publications reported the occurrence of osteonecrosis of the jaw in patients undergoing treatment with bisphosphonates. The mechanism by which bisphosphonates might contribute to the development of osteonecrosis of the jaw is far from being fully elucidated. Suppression of bone turnover, infection, tissue hypoxia and cellular toxicity were proposed as possible mechanisms by which bisphosphonates may exert adverse effects on bone metabolism. Here, we studied 25 consecutive patients treated with bisphosphonates for osteoporosis or tumoral pathologies. We provide good evidence of hyperactive osteoclastic bone resorption and suggest a direct cytotoxic effect of bisphosphonates on bone tissue through induction of osteocyte cell death. We also demonstrate that bisphosphonates only have limited adverse effects on bone vascular network.
引用
收藏
页码:207 / 213
页数:7
相关论文
共 33 条
  • [1] Osteonecrosis of the jaw under bisphosphonate and antiangiogenic therapies: cumulative toxicity profile?
    Ayllon, J.
    Launay-Vacher, V.
    Medioni, J.
    Cros, C.
    Spano, J. P.
    Oudard, S.
    [J]. ANNALS OF ONCOLOGY, 2009, 20 (03) : 600 - 601
  • [2] Degenerative periodontal-diseases and oral osteonecrosis: The role of gene-environment interactions
    Baldi, D.
    Izzotti, A.
    Bonica, P.
    Pera, P.
    Pulliero, A.
    [J]. MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS, 2009, 667 (1-2) : 118 - 131
  • [3] Visualization of bisphosphonate-induced caspase-3 activity in apoptotic osteoclasts in vitro
    Benford, HL
    McGowan, NWA
    Helfrich, MH
    Nuttall, ME
    Rogers, MJ
    [J]. BONE, 2001, 28 (05) : 465 - 473
  • [4] Bisphosphonates induce apoptosis of stromal tumor cells in giant cell tumor of bone
    Cheng, YY
    Huang, L
    Lee, KM
    Xu, JK
    Zheng, MH
    Kumta, SM
    [J]. CALCIFIED TISSUE INTERNATIONAL, 2004, 75 (01) : 71 - 77
  • [5] Visualizing mineral binding and uptake of bisphosphonate by osteoclasts and non-resorbing cells
    Coxon, Fraser P.
    Thompson, Keith
    Roelofs, Anke J.
    Ebetino, F. Hal
    Rogers, Michael J.
    [J]. BONE, 2008, 42 (05) : 848 - 860
  • [6] Dimitrakopoulos I, 2006, INT J ORAL MAX SURG, V35, P588, DOI 10.1016/j.ijom.2006.02.022
  • [7] Diabetes and the risk of osteonecrosis of the jaw
    Favus, Murray J.
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2007, 92 (03) : 817 - 818
  • [8] In vivo effects of bisphosphonates on the osteoclast mevalonate pathway
    Fisher, JE
    Rodan, GA
    Reszka, AA
    [J]. ENDOCRINOLOGY, 2000, 141 (12) : 4793 - 4796
  • [9] Bisphosphonates: Mechanisms of action
    Fleisch, H
    [J]. ENDOCRINE REVIEWS, 1998, 19 (01) : 80 - 100
  • [10] Fournier P, 2002, CANCER RES, V62, P6538